Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells $85,343.72 in Stock

NovoCure Limited (NASDAQ:NVCR) insider Uri Weinberg sold 6,412 shares of NovoCure stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $85,343.72. Following the transaction, the insider directly owned 267,190 shares in the company, valued at $3,556,298.90. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NovoCure Stock Performance

Shares of NVCR stock opened at $13.04 on Friday. The firm has a 50-day moving average of $12.74 and a 200-day moving average of $12.72. The company has a market cap of $1.48 billion, a P/E ratio of -10.69 and a beta of 0.71. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 1.50. NovoCure Limited has a one year low of $9.82 and a one year high of $21.55.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. During the same period last year, the firm earned ($0.61) earnings per share. The firm’s revenue was up 8.2% on a year-over-year basis. Equities research analysts forecast that NovoCure Limited will post -1.3 EPS for the current fiscal year.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Empowered Funds LLC purchased a new stake in shares of NovoCure during the 4th quarter worth approximately $33,000. SJS Investment Consulting Inc. purchased a new position in NovoCure in the third quarter valued at approximately $41,000. Kestra Advisory Services LLC purchased a new position in NovoCure in the fourth quarter valued at approximately $49,000. Larson Financial Group LLC grew its holdings in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 3,562 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in NovoCure by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 1,120 shares during the period. 84.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

NVCR has been the subject of several recent analyst reports. HC Wainwright upped their target price on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Wedbush reissued a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research report on Thursday, January 15th. Finally, Evercore set a $20.00 price objective on NovoCure in a research note on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, NovoCure currently has an average rating of “Hold” and a consensus target price of $26.93.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.